Liz Bloink Joins Connexion Healthcare as Senior Vice President of the Rare Disease and Neuroscience Centers of Excellence
Newtown, PA—June 17, 2014—Connexion Healthcare announces the addition of Liz Bloink as Senior Vice President of the Rare Disease and Neuroscience Centers of Excellence. In this role, she will be responsible for the overall management of the Rare Disease and Neuroscience business units and for the continued growth and development of these units related to new business opportunities for Connexion Healthcare.
Ms Bloink has 25 years of experience in healthcare communications, including holding senior positions in advertising, publications, and continuing medical education. She has been working in the field of neuroscience for more than 10 years, with experience in investigational products and launching new products for various diseases such as schizophrenia, bipolar disorder, Alzheimer’s disease, Parkinson’s disease, and drug-induced movement disorders.
Ms Bloink most recently served as Senior Vice President for a medical communications company in New York, NY, where she managed the agency’s largest clients, supported and mentored account and scientific teams, and was responsible for both organic and new business growth. Ms Bloink’s strong background and extensive experience in client services, account management, project management, business development, process development, and personnel management make her a critical asset to Connexion Healthcare.
Connexion is comprised of 3 Centers of Excellence—Oncology, Rare Disease, and Neuroscience—and possesses core expertise in these therapeutic areas and the nuances involved in each therapeutic landscape. Within these Centers of Excellence, we conceive, develop, and execute scientific communications designed to elucidate the mechanisms, effects, and therapeutic roles of specific clinical entities through an orchestration of publications, presentations, and multimedia programming. Our esteemed medical directors and content development team along with an accounts team rooted in science and best practices are poised and ready to support brands in Phase II development through 2 years postlaunch.